Loading
A phase 3 trial of Taletrectinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT06564324 by Nuvation Bio Inc., with 194 participants planned, started 2024-11-27 and due to reach its primary completion in 2029-01. Interventions recorded: Taletrectinib, Crizotinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvation Bio, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.